Early HIV vaccine trial shows promise – but still a long way to go
NCT ID NCT04844775
First seen Jun 11, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This Phase 1 trial tested a new HIV vaccine in 68 healthy adults to see if it is safe and triggers an immune response. The vaccine uses a DNA-based approach combined with an HIV protein to train the body to fight the virus. While early results are encouraging, this is just the first step – much more research is needed to know if it can actually prevent HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHUV
Lausanne, Canton of Vaud, 1011, Switzerland
-
CIC Cochin
Paris, Paris Cedex 14, 75679, France
-
Chelsea and Westminster Hospital
London, SW10 9NH, United Kingdom
-
Hôpital Henri Mondor
Créteil, Paris, 94010, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIV vaccine (DREP-HIV-PT1 and CN54gp140+MPLA-L)
What this could lead to
If successful, this could point toward a safe and effective HIV vaccine that prevents infection.
What could go wrong
This is a very early Phase 1 trial with only 68 participants. It only tests safety and immune response, not whether the vaccine actually prevents HIV. Many early vaccines fail in later stages.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.